| 854.65 3.635 (0.43%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1001.53  |
1-year : | 1169.79 |
| Resists | First : | 857.47 |
Second : | 1001.53 |
| Pivot price | 830.04 |
|||
| Supports | First : | 790.9 |
Second : | 749.75 |
| MAs | MA(5) : | 839.15 |
MA(20) : | 827.98 |
| MA(100) : | 695.26 |
MA(250) : | 643.82 |
|
| MACD | MACD : | 17.9 |
Signal : | 18.7  |
| %K %D | K(14,3) : | 90.3 |
D(3) : | 83.3 |
| RSI | RSI(14): 69.2 |
|||
| 52-week | High : | 857.47 | Low : | 510.05 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ARGX ] has closed below upper band by 2.7%. Bollinger Bands are 40.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 857.99 - 860.53 | 860.53 - 863.37 |
| Low: | 831.2 - 834.31 | 834.31 - 837.79 |
| Close: | 849.12 - 853.85 | 853.85 - 859.15 |
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Fri, 07 Nov 2025
ARGX: JP Morgan Raises Price Target, Maintains Overweight Rating - GuruFocus
Fri, 07 Nov 2025
Evaluating argenx (ENXTBR:ARGX): Does Market Momentum Reflect True Valuation? - Yahoo Finance
Fri, 07 Nov 2025
J.P. Morgan Maintains Argenx SE(ARGX.US) With Buy Rating, Raises Target Price to $925 - 富途牛牛
Mon, 03 Nov 2025
argenx SE (ARGX) Rose due to Increased Sales of its Vyvgart Medication - Yahoo Finance
Fri, 31 Oct 2025
Wedbush Sticks to Its Buy Rating for Argenx Se (ARGX) - The Globe and Mail
Fri, 31 Oct 2025
HC Wainwright & Co. Maintains argenx SE - Depositary Receipt (ARGX) Buy Recommendation - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 55 (%) |
| Shares Short | 1,860 (K) |
| Shares Short P.Month | 1,740 (K) |
| EPS | 19.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 99.66 |
| Profit Margin | 41 % |
| Operating Margin | 21 % |
| Return on Assets (ttm) | 4.8 % |
| Return on Equity (ttm) | 24.7 % |
| Qtrly Rev. Growth | 97.5 % |
| Gross Profit (p.s.) | 26.47 |
| Sales Per Share | 50.67 |
| EBITDA (p.s.) | 7.61 |
| Qtrly Earnings Growth | 735.2 % |
| Operating Cash Flow | 404 (M) |
| Levered Free Cash Flow | 258 (M) |
| PE Ratio | 43.56 |
| PEG Ratio | 0 |
| Price to Book value | 8.57 |
| Price to Sales | 16.86 |
| Price to Cash Flow | 130.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|